ArticleDrug delivery and translational research2019
An injectable alginate/extra cellular matrix (ECM) hydrogel towards acellular treatment of heart failure.
Article in Drug delivery and translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Toward strategies to advance the conductive properties of hydrogel formulations for cardiac tissue engineering.iScience · 2025Review
- Review
- Programming temporal stiffness cues within extracellular matrix hydrogels for modelling cancer niches.Materials today. Bio · 2024Article
- Recent Advances in Alginate-Based Hydrogels for Cell Transplantation Applications.Pharmaceutics · 2024Review
- Decellularized extracellular matrix materials for treatment of ischemic cardiomyopathy.Bioactive materials · 2024Review
- Decellularized extracellular matrix-based composite scaffolds for tissue engineering and regenerative medicine.Regenerative biomaterials · 2024Review
- Multifunctional ADM hydrogel containing endothelial cell-exosomes for diabetic wound healing.Materials today. Bio · 2023Article
- Recent advances in soluble decellularized extracellular matrix for heart tissue engineering and organ modeling.Journal of biomaterials applications · 2023Review
- Alginate-Chitosan Hydrogels Containing shRNA Plasmid for Inhibition of CTNNB1 Expression in Breast Cancer Cells.Gels (Basel, Switzerland) · 2023Article
- The Role of Hydrogel in Cardiac Repair and Regeneration for Myocardial Infarction: Recent Advances and Future Perspectives.Bioengineering (Basel, Switzerland) · 2023Review
- Tropoelastin Improves Post-Infarct Cardiac Function.Circulation research · 2023Article
- Alginate-Based Composites for Corneal Regeneration: The Optimization of a Biomaterial to Overcome Its Limits.Gels (Basel, Switzerland) · 2022Review
- 3D-bioprinted cancer-on-a-chip: level-up organotypic in vitro models.Trends in biotechnology · 2022Review
- Bioinks Enriched with ECM Components Obtained by Supercritical Extraction.Biomolecules · 2022Article
- Is extracellular matrix (ECM) a promising scaffold biomaterial for bone repair?Histology and histopathology · 2021Review
- Article
- Autonomously Propelled Colloids for Penetration and Payload Delivery in Complex Extracellular Matrices.Micromachines · 2021Review
- In vitro comparison of harvesting site effects on cardiac extracellular matrix hydrogels.Journal of biomedical materials research. Part A · 2021Article
- Improved Models of Human Endometrial Organoids Based on Hydrogels from Decellularized Endometrium.Journal of personalized medicine · 2021Article
- Injectable Myocardial Matrix Hydrogel Mitigates Negative Left Ventricular Remodeling in a Chronic Myocardial Infarction Model.JACC. Basic to translational science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As treatments for myocardial infarction (MI) continue to improve, the population of people suffering from heart failure (HF) is rising significantly. Novel treatment strategies aimed at achieving long-term functional stabilisation and improvement in heart function post MI include the delivery of biomaterial hydrogels and myocardial matrix-based therapies to the left ventricle wall. Individually alginate hydrogels and myocardial matrix-based therapies are at the most advanced stages of commercial/clinical development for this potential treatment option. However, despite these individual successes, the potential synergistic effect gained by combining the two therapies remains unexplored. This study serves as a translational step in evaluating the minimally invasive delivery of dual acting alginate-based hydrogels to the heart. We have successfully developed new production methods for hybrid alginate/extracellular matrix (ECM) hydrogels. We have identified that the high G block alginate/ECM hybrid hydrogel has appropriate rheological and mechanical properties (1.6 KPa storage modulus, 29 KPa compressive modulus and 14 KPa dynamic modulus at day 1) and can be delivered using a minimally invasive delivery device. Furthermore, we have determined that these novel hydrogels are not cytotoxic and are capable of enhancing the metabolic activity of dermal fibroblasts in vitro (p < 0.01). Overall these results suggest that an effective minimally invasive HF treatment option could be achieved by combining alginate and ECM particles.
Indexed as
Identifiers
30511249What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.